Follow-up evaluation of patients with liver test abnormalities detected during SARS-CoV2 infection.

Abnormal liver function tests (A-LFTs) during admission for coronavirus disease-19 (COVID-19) are frequent, but its evolution after COVID-19 resolution remains unexplored. We evaluated factors related to A-LFTs during COVID-19 and assessed the liver outcome after patients' discharge. This is a observational study including: (1) retrospective analysis of variables related to A-LFTs during COVID-19; and (2) follow-up evaluation with blood test, transient elastography and liver biopsy in those with persistent A-LFTs. A-LFTs were defined according to CTCAEv4.0. Among 595 patients, 366 (61.5%) showed A-LFTs. The ratio of partial pressure of oxygen and inspired oxygen fraction (P/F) below 200, ferritin ≥1000 ng/mL, male gender and antibiotic and immunomodulatory treatments were related to A-LFTs. Follow-up evaluation was performed in 153 individuals. Persistent A-LFTs at follow-up was similar in patients with/without A-LFTs during admission (14.1% vs. 4.9%, p = 0.104). Fifteen (93%) and 58 (39%) patients with/without A-LFTs at follow-up showed metabolic fatty liver disease criteria (p < 0.001), which were histologically confirmed. In conclusion, A-LFTs during COVID-19 were related to infection severity. Abnormalities remitted at follow-up in >80% of patients, and no correlation between A-LFTs at admission and at follow-up was found. Most patients with A-LFTs at follow-up had non-invasive and histologically proven fatty liver disease.

Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability.

BACKGROUND: A pattern of major and minor congenital anomalies, facial dysmorphic features, and neurodevelopmental difficulties, including cognitive and social impairments has been reported in some children exposed to sodium valproate (VPA) during pregnancy. Recognition of the increased risks of in utero exposure to VPA for congenital malformations, and for the neurodevelopmental effects in particular, has taken many years but these are now acknowledged following the publication of the outcomes of several prospective studies and registries. As with other teratogens, exposure to VPA can have variable effects, ranging from a characteristic pattern of major malformations and significant intellectual disability to the other end of the continuum, characterised by facial dysmorphism which is often difficult to discern and a more moderate effect on neurodevelopment and general health. It has become clear that some individuals with FVSD have complex needs requiring multidisciplinary care but information regarding management is currently lacking in the medical literature. METHODS: An expert group was convened by ERN-ITHACA, the European Reference Network for Congenital Malformations and Intellectual Disability comprised of professionals involved in the care of individuals with FVSD and with patient representation. Review of published and unpublished literature concerning management of FVSD was undertaken and the level of evidence from these sources graded. Management recommendations were made based on strength of evidence and consensus expert opinion, in the setting of an expert consensus meeting. These were then refined using an iterative process and wider consultation. RESULTS: Whilst there was strong evidence regarding the increase in risk for major congenital malformations and neurodevelopmental difficulties there was a lack of high level evidence in other areas and in particular in terms of optimal clinical management.. The expert consensus approach facilitated the formulation of management recommendations, based on literature evidence and best practice. The outcome of the review and group discussions leads us to propose the term Fetal Valproate Spectrum Disorder (FVSD) as we feel this better encompasses the broad range of effects seen following VPA exposure in utero. CONCLUSION: The expert consensus approach can be used to define the best available clinical guidance for the diagnosis and management of rare disorders such as FVSD. FVSD can have medical, developmental and neuropsychological impacts with life-long consequences and affected individuals benefit from the input of a number of different health professionals.

Efficacy of passive hypothermia and adverse events during transport of asphyxiated newborns according to the severity of hypoxic-ischemic encephalopathy.

OBJECTIVE: To determine if the efficacy of passive hypothermia and adverse events during transport are related to the severity of neonatal hypoxic-ischemic encephalopathy. METHODS: This was a retrospective study of 67 infants with hypoxic-ischemic encephalopathy, born between April 2009 and December 2013, who were transferred for therapeutic hypothermia and cooled during transport. RESULTS: Fifty-six newborns (84%) were transferred without external sources of heat and 11 (16%) needed an external heat source. The mean temperature at departure was 34.4±1.4°C and mean transfer time was 3.3±2.0h. Mean age at arrival was 5.6±2.5h. Temperature at arrival was between 33 and 35°C in 41 (61%) infants, between 35°C and 36.5°C in 15 (22%) and <33°C in 11 (16%). Infants with severe hypoxic-ischemic encephalopathy had greater risk of having an admission temperature<33°C (OR: 4.5; 95% CI: 1.1-19.3). The severity of hypoxic-ischemic encephalopathy and the umbilical artery pH were independent risk factors for a low temperature on admission (p<0.05). Adverse events during transfer, mainly hypotension and bleeding from the endotracheal tube, occurred in 14 infants (21%), with no differences between infants with moderate or severe hypoxic-ischemic encephalopathy. CONCLUSION: The risk of overcooling during transport is greater in newborns with severe hypoxic-ischemic encephalopathy and those with more severe acidosis at birth. The most common adverse events during transport are related to physiological deterioration and bleeding from the endotracheal tube. This observation provides useful information to identify those asphyxiated infants who require closer clinical surveillance during transport.

Can cerebellar and brainstem apparent diffusion coefficient (ADC) values predict neuromotor outcome in term neonates with hypoxic-ischemic encephalopathy (HIE) treated with hypothermia?

BACKGROUND AND PURPOSE: To determine the apparent diffusion coefficient (ADC) in specific infratentorial brain structures during the first week of life and its relation with neuromotor outcome for Hypoxic-ischemic encephalopathy (HIE) in term neonates with and without whole-body hypothermia (TH). MATERIALS AND METHODS: We retrospectively evaluated 45 MRI studies performed in the first week of life of term neonates born between 2010 and 2013 at Boston Children's Hospital. Selected cases were classified into three groups: 1) HIE neonates who underwent TH, 2) HIE normothermics (TN), and 3) controls. The neuromotor outcome was categorized as normal, abnormal and death. The ADCmean was calculated for six infratentorial brain regions. RESULTS: A total of 45 infants were included: 28 HIE TH treated, 8 HIE TN, and 9 controls. The mean gestational age was 39 weeks; 57.8% were male; 11.1% were non-survivors. The median age at MRI was 3 days (interquartile range, 1-4 days). A statistically significant relationship was shown between motor outcome or death and the ADCmean in the vermis (P = 0.002), cerebellar left hemisphere (P = 0.002), midbrain (P = 0.009), pons (P = 0.014) and medulla (P = 0.005). In patients treated with TH, the ADC mean remained significantly lower than that in the controls only in the hemispheres (P = 0.01). In comparison with abnormal motor outcome, ADCmean was lowest in the left hemisphere (P = 0.003), vermis (P = 0.003), pons (P = 0.0036) and medulla (P = 0.008) in case of death. CONCLUSION: ADCmean values during the first week of life in the left hemisphere, vermis, pons and medulla are related to motor outcome or death in infants with HIE either with or without hypothermic therapy. Therefore, this objective tool can be assessed prospectively to determine if it can be used to establish prognosis in the first week of life, particularly in severe cases of HIE.

Near infrared spectroscopy in the management of status epilepticus in a young infant.

We report the medication management of electroencephalographic status epilepticus with subtle clinical manifestations in a young infant while simultaneously recording electroencephalographic activity and cerebral regional oxygen saturation (rSO(2)) index using near infrared spectroscopy (NIRS). We found that antiepileptic drugs equally influence the frequency of rSO(2) index fluctuations and electroencephalographic seizures. The purpose of this report is to illustrate the use of NIRS in the medication management of an infant with status epilepticus and subtle or no clinical manifestations; and to suggest that if future studies confirm our finding, NIRS may be reliably used to gauge the effects of antiepileptic medications in similar patients.

Efficacy of passive hypothermia and adverse events during transport of asphyxiated newborns according to the severity of hypoxic-ischemic encephalopathy / Eficácia da hipotermia passiva e eventos adversos durante o transporte de recém-nascidos asfixiados de acordo com a gravidade da encefalopatia hipóxico-isquêmica

Abstract Objective To determine if the efficacy of passive hypothermia and adverse events during transport are related to the severity of neonatal hypoxic-ischemic encephalopathy. Methods This was a retrospective study of 67 infants with hypoxic-ischemic encephalopathy, born between April 2009 and December 2013, who were transferred for therapeutic hypothermia and cooled during transport. Results Fifty-six newborns (84%) were transferred without external sources of heat and 11 (16%) needed an external heat source. The mean temperature at departure was 34.4 ± 1.4 °C and mean transfer time was 3.3 ± 2.0 h. Mean age at arrival was 5.6 ± 2.5 h. Temperature at arrival was between 33 and 35 °C in 41 (61%) infants, between 35 °C and 36.5 °C in 15 (22%) and <33 °C in 11 (16%). Infants with severe hypoxic-ischemic encephalopathy had greater risk of having an admission temperature < 33 °C (OR: 4.5; 95% CI: 1.1-19.3). The severity of hypoxic-ischemic encephalopathy and the umbilical artery pH were independent risk factors for a low temperature on admission (p < 0.05). Adverse events during transfer, mainly hypotension and bleeding from the endotracheal tube, occurred in 14 infants (21%), with no differences between infants with moderate or severe hypoxic-ischemic encephalopathy. Conclusion The risk of overcooling during transport is greater in newborns with severe hypoxic-ischemic encephalopathy and those with more severe acidosis at birth. The most common adverse events during transport are related to physiological deterioration and bleeding from the endotracheal tube. This observation provides useful information to identify those asphyxiated infants who require closer clinical surveillance during transport.

Resumo Objetivo Determinar se a eficácia da hipotermia passiva e eventos adversos durante o transporte estão relacionados à gravidade da encefalopatia hipóxico-isquêmica neonatal. Métodos Estudo retrospectivo de 67 neonatos com encefalopatia hipóxico-isquêmica (nascidos entre abril de 2009 e dezembro de 2013) transferidos para hipotermia terapêutica e resfriados durante o transporte. Resultados Foram transportados 56 recém-nascidos (84%) sem fontes externas de calor e 11 (16%) precisaram de uma fonte externa de calor. A temperatura média na saída foi de 34,4 ± 1,4 °C e o tempo médio de transporte foi de 3,3 ± 2,0 horas. A idade média na chegada foi de 5,6 ± 2,5 horas. A temperatura na chegada ficou entre 33-35 °C em 41 (61%) neonatos, entre 35°-36,5 °C em 15 (22%) e < 33 °C em 11 (16%). Neonatos com encefalopatia hipóxico-isquêmica grave apresentaram maior risco de temperatura < 33 °C na internação (RC 4,5; IC de 95% 1,1-19,3). A gravidade da encefalopatia hipóxico-isquêmica e o pH da artéria umbilical foram fatores de risco independentes para uma baixa temperatura na internação (p < 0,05). Eventos adversos durante o transporte, principalmente hipotensão e sangramento do tubo endotraqueal, ocorreram em 14 neonatos (21%), sem diferenças entre neonatos com encefalopatia hipóxico-isquêmica moderada ou grave. Conclusão O risco de super-resfriamento durante o transporte é maior em recém-nascidos com encefalopatia hipóxico-isquêmica grave e naqueles com acidose mais grave no nascimento. Os eventos adversos mais comuns durante o transporte estão relacionados a deterioração fisiológica e sangramento do tubo endotraqueal. Essa observação fornece informações úteis para identificar neonatos asfixiados que exigem maior vigilância clínica durante o transporte.

Confianza y actitud tras un diagnóstico negativo de alergia a fármacos betalactámicos y/o AINE / Trust and attitude after a negative diagnosis for allergy to betalactam drugs and/or NSAIDs

Objetivo: determinar el grado de confianza en el diagnóstico de exclusión de alergia en pacientes con sospecha de hipersensibilidad a antibióticos betalactámicos y/o AINE. Adicionalmente se pretendía describir la actitud del paciente hacia la toma futura del fármaco que motivó el estudio.Método: se realizó un estudio descriptivo transversal. Se seleccionaron 103 pacientes mayores de 18 años, de ambos sexos y con un resultado negativo en las pruebas diagnósticas de alergia a betalactámicos y/o AINE. Los participantes fueron evaluados mediante un cuestionario heteroadministrado en la práctica clínica habitual de alergología.Resultados: el grado de confianza hacia la etiqueta previa de alergia fue moderado para antibióticos betalactámicos (6,4/10) y para AINE (6,1/10), elevado hacia el diagnóstico negativo de alergia (betalactámicos: 7,5/10; AINE: 7,9/10), y moderado con relación a la futura toma del fármaco estudiado, tras un diagnóstico negativo de alergia (betalactámicos: 6,7/10; AINE: 6,3/10). El grado de confianza hacia el diagnóstico de exclusión de alergia a betalactámicos o AINE aumenta con relación al conferido previamente por el de sospecha, en ambos fármacos (p= 0,01).Conclusiones: el grado de confianza de los pacientes en el diagnóstico de exclusión de alergia a fármacos betalactámicos y/o AINE es elevado. Sin embargo, la confianza para la toma futura del fármaco que motivó el estudio, tras un diagnóstico negativo de alergia, se reduce a moderada. Los profesionales de la salud deben proporcionar una educación sanitaria efectiva que resuelva las inseguridades hacia la realización de la prueba y refuerce la confianza del paciente para la toma futura del fármaco.(AU)

Objective: to determine the level of trust in the diagnosis excluding allergy in patients with suspected hypersensitivity to betalactam antibiotics and/or NSAIDs. Additionally, it was intended to describe the attitude of patients towards taking in the future the drug which motivated the study.Method: a descriptive cross-sectional study was conducted; 103 >18-year old patients were selected, of both genders and with a negative result in diagnostic tests for betalactam drugs and/or NSAIDs. Participants were evaluated through a heteroadministered questionnaire at their usual Allergology clinical practice.Results: the level of trust towards the previous allergy label was moderate for betalactam antibiotics (6.4/10) and for NSAIDs (6.1/10), high towards the negative diagnosis for allergy (betalactam drugs: 7.5/10; NSAIDs: 7.9/10), and moderate regarding taking in the future the drug under study, after a negative diagnosis for allergy (betalactam drugs: 6.7/10; NSAIDs: 6.3/10). The degree of trust towards the diagnosis excluding allergy to betalactam drugs or NSAIDs increased regarding the previous degree for suspected allergy, in both drugs (p= 0.01).Conclusions: there is a high degree of trust in patients regarding their diagnosis excluding allergy to betalactam drugs and/or NSAIDs. However, trust regarding taking in the future the drug which motivated the study, after a negative diagnosis of allergy, was reduced to moderate. Health professionals must provide effective health education that solves uncertainties in terms of conducting the test and reinforces trust by patients for taking the drug in the future.(AU)

Radiología intervencionista paliativa: una mirada sobre nuestra experiencia / Palliative interventional radiology: a review of our experience

Introducción: El Intervencionismo paliativo se ha convertido en una alternativa válida a tener en cuenta en los pacientes con enfermedades oncológicas avanzadas, cercanas al final de la vida, sin otras opciones de tratamiento, para conseguir mejorar el control sintomático de las complicaciones que se derivan de su enfermedad, cuando los tratamientos convencionales no son posibles. El objetivo de este estudio es analizar la supervivencia de los pacientes después de la realización de cualquier técnica intervencionista paliativa y evaluar las posibles complicaciones derivadas de la técnica. Material y métodos: Estudio observacional, descriptivo y prospectivo. Se incluyeron todos los pacientes atendidos por nuestra unidad a quienes se les indicó una técnica intervencionista. Se analizaron variables demográfi cas y clínicas, así como las técnicas más frecuentemente utilizadas, la supervivencia postintervención y las complicaciones que presentaron los pacientes después del procedimiento. Resultados: Se incluyeron 26 pacientes, todos con enfermedades oncológicas avanzadas, sin opciones de tratamiento oncoespecífi co, a los cuales se les realizó alguna técnica intervencionista indicada para control sintomático. La supervivencia postintervención fue de 43 días de mediana. Nueve pacientes presentaron complicaciones postintervención, pero estas fueron de carácter leve en la mayoría de los casos, y se resolvieron con tratamiento conservador, sin precisar recambio del dispositivo en la mayoría de los casos. Conclusión: Las técnicas de radiología intervencionista disponibles son una alternativa válida y segura para utilizar en el caso de pacientes oncológicos sin opciones de tratamiento curativo, con pronóstico limitado a las etapas fi nales de la vida, con el objetivo de mejorar el control sintomático. (AU)

Introduction: Palliative interventionism has become a valid alternative to consider in patients with advanced oncological disease, close to the end of life, without further treatment possibilities, to provide improved symptomatic control of the complications derived from their disease, when conventional treatments are not possible. The aim of this study was to analyze patient survival after any palliative interventional technique, and to assess potential technique-derived complications. Patients and methods: An observational, descriptive, prospective study was carried out. All patients in our unit who were candidates to undergo an interventional technique were included. Demographic and clinical variables were analyzed, as were the most commonly used techniques, postprocedural survival, and the complications presented by patients after the intervention. Results: Twenty-six patients were included in the study, all of them with oncological advanced disease, without options for an oncospecific treatment. A suitable interventional technique was performed for all these patients to achieve symptomatic control. Postprocedural survival was 43 days on median. Nine patients had postprocedural complications, but these were mild in a majority of cases and were solved with conservative treatment, requiring no device replacement in most cases. Conclusions: Available interventional radiology techniques are a valid and safe alternative to use in the case of advanced cancer patients when a medical and/or surgical traditional treatment is not recommended, with the aim of improving symptom control. (AU)

[Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics]. / Prevalencia de síntomas de ansiedad y de depresión en pacientes con artritis psoriásica en consultas de reumatología.

UNLABELLED: FUNDAMENTAL AND OBJECTIVE: Psychological impairment is frequent in patients with rheumatic diseases. The aim of the study was to assess the prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics. PATIENTS AND METHOD: Multicentre cross-sectional study conducted in rheumatology clinics. Patients with psoriatic arthritis were recruited; variables retrieved were sociodemographic, clinical and patient centered (Hospital Anxiety and Depression scale o HADs, EQ-5D questionnaire, etc.). Prevalence in the study population was calculated as anxiety or depression symptoms by an HADs score ≥11 or those receiving pharmacological treatment. A logistics regression model was used to know which variables were related to symptoms of anxiety or depression. RESULTS: A total of 495 patients were included, 42.8% were women and median (SD) age was 50.4 (12.7) years. Prevalence of symptoms of anxiety were 29.7% and prevalence of symptoms of depression was 17,6%. Patients with anxiety or depression symptoms had all EQ-5D dimensions affected (p<0.01). Higher prevalence of anxiety was related to being a woman, a mixed onset pattern with respect to peripheral joints and those treated with DMARD alone with respect to DMARD+NSAID or biologic alone. A higher depression prevalence was related to being a woman and a mixed onset pattern with respect to peripheral joints. CONCLUSION: The prevalence of anxiety symptoms and the prevalence of depression symptoms are high among patients suffering psoriatic arthritis in the studied population.

Neonato afecto del síndrome del ácido valproico fetal / Newborn with fetal valproic acid syndrom

Introducción. El síndrome del ácido valproico fetal consiste en alteraciones congénitas que aparecen en el feto expuesto a tratamiento gestacional con ácido valproico. El ácido valproico, el antiepiléptico más teratogénico, es utilizado ampliamente en gestantes afectas de epilepsia. Las estrategias de prevención, sospecha y detección precoz de este síndrome son de vital importancia, ya que el inicio precoz del estudio y tratamiento permite ofrecer una mejoría en la calidad de vida del paciente. Caso clínico. Se presenta el caso clínico de un recién nacido afecto del síndrome del ácido valproico fetal. En el paciente destacaba una facies peculiar con microtia bilateral. Al alta fue seguido por Otorrinolaringología, para la realización de pruebas audiológicas y colocación de audífonos, y por Cirugía, para realizar la reconstrucción de los pabellones auriculares. Comentarios. El estudio en los casos de microtia consiste en la realización de pruebas de imagen (Tomografía computeritzada craneal), para comprobar el grado de afectación del oído medio e interno, y pruebas audiológicas para conocer el umbral auditivo del paciente, hipoacusia moderada de transmisión en la mayoría de los casos. El tratamiento persigue una estimulación precoz del oído para favorecer el lenguaje mediante la colocación de audífonos de transmisión ósea. El tratamiento quirúrgico se realiza a partir de los 10 años de vida, y consiste en la reconstrucción de un pabellón auricular en tres dimensiones a partir de cartílago costal(AU)

Introduction. The fetal valproic acid syndrome consists of congenital abnormalities occurring in the fetus exposed to gestational treatment with valproic acid; this drug is the most teratogenic antiepileptical treatment that is used in pregnant women suffering from epilepsy. Strategies for prevention and early diagnosis of this syndrome are key since early evaluation and treatment can improve significantly the quality of life of these patients. Case report. We report the case of a newborn affected by fetal valproic syndrome, who presented with an abnormal facies with severe microtia bilaterally. The patient was subsequently followed by otorhinolaryngology for audiology evaluation and placement of hearing aids, followed by reconstructive surgery of the earlobes. Comments. The diagnostic evaluation of microtia involves neuroimaging for assessing the degree of involvement of the middle and inner ear, and audiology evaluation, which shows moderate conductive hearing loss in most cases. Treatment aims to stimulating early hearing to promote language through the placement of bone transmission hearing aids. Surgical treatment is usually not recommended until 10 years of age, and it includes 3-dimensional ear reconstruction using rib cartilage(AU)

Prevalencia de síntomas de ansiedad y de depresión en pacientes con artritis psoriásica en consultas de reumatología / Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics

Fundamento y objetivo. Las alteraciones psicológicas son frecuentes entre pacientes con enfermedades reumáticas. El objetivo del estudio fue conocer la prevalencia de los síntomas de ansiedad y depresión en pacientes con artritis psoriásica que acuden a consultas de reumatología. Pacientes y método. Estudio transversal multicéntrico en consultas de reumatología. Se seleccionaron pacientes con artritis psoriásica; se recogieron variables sociodemográficas, clínicas y centradas en el paciente (Escala Hospitalaria de Ansiedad y Depresión o HADs, cuestionario EQ-5D, etc.). Se calculó la prevalencia de síntomas de ansiedad y depresión en esta población según una puntuación ≥11 en HADs o estar recibiendo tratamiento farmacológico. Se utilizó un modelo de regresión logística para conocer las variables relacionadas con la presencia de síntomas de ansiedad o depresión. Resultados. Se incluyeron 495 pacientes, 42,8% mujeres y edad media (DE) de 50,4 (12,7) años. La prevalencia de síntomas de ansiedad fue 29,7% y 17,6% de depresión. Los pacientes con síntomas de ansiedad o depresión presentaron mayor afectación en todas las dimensiones del EQ-5D (p<0,01). La mayor prevalencia en la población de estudio de ansiedad se relacionó con ser mujeres, patrón de debut mixto respecto al periférico y en tratamiento con FAME en monoterapia respecto a FAME+AINES o biológico en monoterapia. La mayor prevalencia de depresión se relacionó con ser mujeres y patrón de debut mixto respecto al periférico. Conclusión. La prevalencia de síntomas de ansiedad y de depresión es elevada en pacientes con artritis psoriásica en la población de este estudio (AU)

Fundamental and Objective. Psychological impairment is frequent in patients with rheumatic diseases. The aim of the study was to assess the prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics. Patients and method. Multicentre cross-sectional study conducted in rheumatology clinics. Patients with psoriatic arthritis were recruited; variables retrieved were sociodemographic, clinical and patient centered (Hospital Anxiety and Depression scale o HADs, EQ-5D questionnaire, etc.). Prevalence in the study population was calculated as anxiety or depression symptoms by an HADs score ≥11 or those receiving pharmacological treatment. A logistics regression model was used to know which variables were related to symptoms of anxiety or depression. Results. A total of 495 patients were included, 42.8% were women and median (SD) age was 50.4 (12.7) years. Prevalence of symptoms of anxiety were 29.7% and prevalence of symptoms of depression was 17,6%. Patients with anxiety or depression symptoms had all EQ-5D dimensions affected (p<0.01). Higher prevalence of anxiety was related to being a woman, a mixed onset pattern with respect to peripheral joints and those treated with DMARD alone with respect to DMARD+NSAID or biologic alone. A higher depression prevalence was related to being a woman and a mixed onset pattern with respect to peripheral joints. Conclusion. The prevalence of anxiety symptoms and the prevalence of depression symptoms are high among patients suffering psoriatic arthritis in the studied population (AU)